Successful Re-administration of Low-dose of Methimazole (MMI) in Graves’ Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU)

Sumihisa Kubota

Abstract

Objective When patients with Graves’ disease show severe allergic cutaneous reactions, physicians often suggest that they undergo radioiodine therapy instead of receiving propylthiouracil (PTU), another antithyroid drug, because anti-neutrophil cytoplasmic antibody (ANCA)-related vasculitis can occur with PTU, especially with long-term use. However, some patients refuse radioiodine therapy and chose PTU. Sometimes PTU treatment may be prolonged. Since the frequency of adverse effects of methimazole (MMI) is dose-related, there is a possibility that we can re-administer a low dose without adverse effects to patients well-controlled with PTU who once experienced an allergic reaction to MMI.

Methods I prospectively re-administered a low dose of MMI to patients who previously experienced an allergic reaction to MMI at initial treatment. The dose of re-administered MMI ranged from 5 mg twice a week to 5 mg daily.

Patients Nine patients with Graves’ disease who developed urticaria at initial treatment with MMI and had been treated with PTU for 6 to 21 years were recruited.

Results Eight of the 9 patients were successfully controlled with MMI without allergic cutaneous reactions. Only one patient felt itchiness 2 days after switching to MMI. However, skin change was not observed.

Conclusion If the patients show allergic cutaneous reactions as a side effect of MMI at the initial treatment for Graves’ disease, then there is a strong possibility that such patients can tolerate a low dose of MMI without adverse effects after the disease activity has subsided.

Key words: Graves’ disease, methimazole, propylthiouracil, adverse effect, re-administration

(Intern Med 55: 3235-3237, 2016) (DOI: 10.2169/internalmedicine.55.7281)
Table. Patients’ Data at the Diagnosis of Graves’ Disease and on Re-exposure to MMI.

| Patient | Sex | Age (yr) | FT4 (ng/dL) | TSH (mIU/L) | TRAb (IU/mL) | Thyroid volume (mm³) | The daily dose of MMI (mg) | Course | Treatment period (months) | Age | FT4 (ng/dL) | TSH (mIU/L) | TRAb (IU/mL) | Dosage of PTU (mg) |
|---------|-----|----------|-------------|-------------|--------------|---------------------|-------------------------|--------|--------------------------|-----|-------------|--------------|---------------|----------------|
| 1       | F   | 47       | 4.5*        | >0.05*      | 6.1* RUL     | 20                  | 30                      | relapse | 6                        | 53  | 1.26        | 1.08         | <0.3          | 25 mg every second day |
| 2       | F   | 36       | 2.95*       | >0.05*      | 69%          | 31.7                | 30                      | relapse | 8                        | 43  | 1.54        | 0.99         | 0.86         | 5 mg every second day |
| 3       | F   | 33       | -           | -           | -            | 100                 | 30                      | relapse | 8                        | 42  | 1.33        | 1.24         | 1.03         | 200 mg every second day |
| 4       | F   | 30       | 2.27*       | <0.005*     | 19.39%       | -                   | 15                      | relapse | 9                        | 39  | 1.2         | 0.73         | 0.64         | 50 mg every second day |
| 5       | F   | 65       | 1.98*       | >0.005*     | 19.39%       | -                   | 5                       | relapse | 10                       | 75  | 1           | 2.55         | 1.65         | 25 mg every second day |
| 6       | F   | 32       | -           | -           | -            | -                   | 15                      | relapse | 10                       | 44  | 1.13        | 1.3          | 6.02         | 50 mg every second day |
| 7       | F   | 31       | -           | -           | -            | 9.5                 | 30                      | relapse | 12                       | 45  | 0.9         | 0.07         | 4.01         | 50 mg every second day |
| 8       | F   | 41       | 3.01*       | <0.005*     | 31.60%       | 25.5                | 20                      | relapse | 14                       | 55  | 1.36        | 2.24         | <0.3          | 50 mg every second day |
| 9       | F   | 15       | 4.70*       | <0.005*     | 81.90%       | 32.3                | 30                      | relapse | 21                       | 36  | 1.42        | 4.67         | 3.27         | 50 mg every second day |

a: TSH, FT4, and FT3 were measured employing ARCHITECT TSH, FT4, and FT3 assays, respectively (Abbott Co., Tokyo, Japan). Normal range: TSH (0.30-5.00 mIU/L), FT4 (0.70-1.60 ng/dL), FT3 (1.70-2.70 pg/mL).
b: TSH, FT4, and FT3 were measured employing AxSYM TSH, FT4, and FT3 assays, respectively (Dainabot Co., Tokyo, Japan). Normal range: TSH (0.40-4.50 mIU/L), FT4 (0.75-1.80 ng/dL), FT3 (2.50-4.50 pg/mL).
c: TRAb was measured with TSH receptor antibody assay kit (RSR Ltd., Cardiff, UK). Normal range: TRAb < 15%.
d: TRAb was measured with an Elecsys TRAb assay (Roche Diagnostics GmbH, Mannheim, Germany). Normal range: TRAb < 1.9 (IU/L).
e: TSH and FT4 were measured with an Elecsys TSH and FT4 assays, respectively (Roche Diagnostics GmbH, Mannheim, Germany). Normal range: TSH (0.30-5.00 mIU/L), FT4 (0.80-1.90 ng/dL).

Evaluation of the thyroid function

TSH, FT4, and FT3 were measured employing AxSYM TSH, FT4, and FT3 assays (Dainabot Co., Tokyo, Japan), respectively, at the diagnosis of Graves’ disease in some patients. In the other patients, TSH, FT4, and FT3 were measured employing ARCHITECT TSH, FT4, and FT3 assays (Abbott Co., Tokyo, Japan), respectively, at the diagnosis of Graves’ disease.

On re-exposure to MMI, TSH, FT4, and FT3 were measured with Elecsys TSH and FT4 assays (Roche Diagnostics GmbH, Mannheim, Germany), respectively. TRAb was measured with a TSH receptor antibody assay (RSR Ltd., Cardiff, UK) or with an Elecsys TRAb assay (Roche Diagnostics GmbH). Normal ranges are described in Table.

Results

Eight of the 9 patients were successfully controlled with MMI without allergic cutaneous reactions. Only one patient (Patient 7) felt itchiness 2 days after switching to MMI. However, skin change was not observed. This patient resumed PTU. No patients showed other adverse effects, and 8 patients maintained a euthyroid state with a low dose of MMI.
Discussion

When patients with Graves’ disease show allergic reactions at initial treatment with MMI, we have several alternative treatments for Graves’ disease, such as radioiodine therapy, thyroidectomy, and the internal use of PTU. Because most Japanese patients prefer PTU rather than radioiodine therapy and thyroidectomy, we have no choice but to use PTU. Although we inform patients of the fact that PTU can cause fulminant hepatic necrosis and ANCA-related vasculitis (1, 2), especially with long-term use, some patients refuse to change their treatment after their thyroid functions are normalized with PTU. Many physicians treat such patient and continue to administer PTU. However, MMI treatment would be much safer for these patients.

In standard treatment of Graves’ disease, we can gradually reduce the dose of MMI (15-30 mg/day to 5-2.5 mg/day). I hypothesized that patients may not show allergic reactions with a low dose of MMI even if they once experienced allergic reactions with a high dose of MMI at initial treatment because it is known that the frequency of adverse effects of MMI is dose-related. The results of this study supported this hypothesis.

Azizi et al. reported that long-term continuous MMI treatment in Graves’ disease is safe and the risks of occurrence of cardiac or bone complications are equal to or less than those of radioiodine therapy (6). Additionally, Villagelin et al. suggested that prolonged low doses of MMI are an alternative choice for relapsed Graves’ disease patients who refuse definitive treatment (7). In this study, 8 patients who were successfully controlled with MMI appeared to benefit from re-administration of MMI.

In conclusion, if patients show allergic cutaneous reactions as a side effect of MMI at initial treatment for Graves’ disease, there is a strong possibility that such patients can tolerate a low dose of MMI without adverse effects after the disease activity has subsided. As a consequence, we can reduce the possibility of ANCA-related vasculitis with PTU in such patients. However, since the re-administration of MMI to patients who experienced an allergic reaction to it at initial treatment may be risky, we should pay very careful attention to severe adverse effects, such as agranulocytosis.

The author states that he has no Conflict of Interest (COI).

References

1. Bahn Chair RS, Burch HB, Cooper DS, et al; American Thyroid Association; American Association of Clinical Endocrinologists. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid 21: 593-646, 2011.
2. Morita S, Ueda Y, Eguchi K. Anti-thyroid drug-induced ANCA-associated vasculitis: a case report and review of the literature. Endocr J 47: 467-470, 2000.
3. Reinwein D, Benker G, Lazarus JH, Alexander WD. A prospective randomized trial of antithyroid drug dose in Graves’ disease therapy. European Multicenter Study Group on Antithyroid Drug Treatment. J Clin Endocrinol Metab 76: 1516-1521, 1993.
4. Nakamura H, Noh JY, Itoh K, Fukata S, Miyauchi A, Hamada N. Comparison of methimazole and propylthiouracil in patients with hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab 92: 2157-2162, 2007.
5. Takata K, Kubota S, Fukata S, et al. Methimazole-induced agranulocytosis in patients with Graves’ disease is more frequent with an initial dose of 30 mg daily than with 15 mg daily. Thyroid 19: 559-563, 2009.
6. Azizi F, Ataie L, Hedayati M, Mehrabi Y, Sheikholeslami F. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol 152: 695-701, 2005.
7. Villagelin D, Romaldini JH, Santos RB, Milkos AB, Ward LS. Outcomes in relapsed Graves’ disease patients following radioiodine or prolonged low dose of methimazole treatment. Thyroid 25: 1282-1290, 2015.

The Internal Medicine is an Open Access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).

© 2016 The Japanese Society of Internal Medicine
http://www.naika.or.jp/imonline/index.html